skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride

Review

(2656) Views  (710) Full article downloads

Authors: Cary O Harding

Published Date August 2010 Volume 2010:4 Pages 231 - 236
DOI: http://dx.doi.org/10.2147/BTT.S3015

Cary O Harding

Departments of Molecular and Medical Genetics and Pediatrics, Oregon Health & Science University, Portland, Oregon, USA

Abstract: Oral administration of sapropterin hydrochloride, recently approved for use by the US Food and Drug Administration and the European Commission, is a novel approach for the treatment of phenylketonuria (PKU), one of the most common inborn errors of metabolism. PKU is caused by an inherited deficiency of the enzyme phenylalanine hydroxylase (PAH), and the pathophysiology of the disorder is related to chronic accumulation of the free amino acid phenylalanine in tissues. Contemporary therapy is based upon restriction of dietary protein intake, which leads to reduction of blood phenylalanine levels. This therapy is difficult to maintain throughout life, and dietary noncompliance is commonplace. Sapropterin dihydrochloride is a synthetic version of tetrahydrobiopterin, the naturally occurring pterin cofactor that is required for PAH-mediated phenylalanine hydroxylation. In a subset of individuals with PAH deficiency, sapropterin administration leads to reduction in blood phenylalanine levels independent of dietary protein. For these individuals, sapropterin is an effective novel therapy for PKU.

Keywords: sapropterin dihydrochloride, phenylketonuria, phenylalanine, tetrahydrobiopterin







Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Challenges in the management of juvenile idiopathic arthritis with etanercept
Safety of etanercept in elderly subjects with rheumatoid arthritis
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
Proteasome inhibition and its therapeutic potential in multiple myeloma
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed